Oak Hill Bio debuts with pipeline and execs from Takeda

Having been a prolific buyer and licensor of medicines, investigational candidates and companies, including its $64 billion acquisition of Shire in 2018, Japanese drug major Takeda Pharmaceutical (TYO: 4502) is also spinning out assets, some into a newly-formed companies such as Ensoma.

The lates such deal is Oak Hill Bio, a clinical-stage rare disease therapeutics compan that launched in the USA today, with plans to advance a pipeline of promising clinical and pre-clinical investigational therapeutics acquired and licensed from Takeda.

Under the terms of the agreements, Takeda will receive an upfront payment, an ownership stake in Oak Hill and potential milestones and royalty payments in exchange for the acquired and licensed programs. Takeda will also support the transition for continued research and development of the acquired programs. The pipeline includes two clinical-stage and four pre-clinical programs.